Hypoactive Delirium
8
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
50%
4 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Rivastigmine for the Treatment of Hypoactive Anticholinergic Delirium and CNS Depression Associated Mainly With Clozapine Poisoning.
A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium
The Basel BOMP-AID Randomized Trial
An Observational Study of Emergence and Hypoactive Delirium After Anesthesia
Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure
A Pilot Study of "Stanford Proxy Test for Delirium" (S-PTD)
Delirium Prevention in Patients From the Intensive Care Unit (DELA)
Treatment of Hypoactive Delirium and Outcome Measures